10
Treatment
Netupitant-palonosetron 300 mg netupitant/0.5 mg
palonosetron oral in single
capsule (NEPA)
Rolapitant 180 mg oral
5-HT
3
receptor antagonist
a
Granisetron 2 mg oral or 1 mg or 0.01 mg/kg
IV or 1 transdermal patch or
10 mg subcutaneous
Ondansetron 8 mg oral twice daily or 8 mg
oral dissolving tablet twice daily
or three 8 mg oral soluble films
or 8 mg or 0.15 mg/kg IV
Palonosetron 0.50 mg oral or 0.25 mg IV
Dolasetron 100 mg oral ONLY
Tropisetron 5 mg oral or 5 mg IV
Ramosetron 0.3 mg IV
Dexamethasone
If aprepitant is used
b
12 mg oral or IV
If fosaprepitant is usedb
12 mg oral or IV
If netupitant-
palonosetron is used
b
12 mg oral or IV
If rolapitant is used 20 mg (oral or IV)
Olanzapine 10 mg oral 10 mg oral on days 2–4
Moderate
d
5-HT
3
receptor antagonist
Granisetron 2 mg oral or 1 mg or 0.01 mg/kg
IV or 1 transdermal patch or
10 mg subcutaneous
Ondansetron 8 mg oral twice daily or 8 mg
oral dissolving tablet twice daily
or 8 mg oral soluble film twice
daily or 8 mg or 0.15 mg/kg IV
Palonosetron 0.50 mg oral or 0.25 mg IV
Dolasetron 100 mg oral ONLY
Tropisetron 5 mg oral or 5 mg IV
Ramosetron 0.3 mg IV
Dexamethasone 8 mg oral or IV 8 mg oral or IV on days
2–3
e
Table 3. Antiemetic Dosing for Adults by Chemotherapy
Risk Category (cont'd)
